(Camptothecin + podofilox) is under clinical development by Neovia Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Camptothecin + podofilox)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Camptothecin + podofilox) overview
Fixed dose combination of camptothecin and podofilox (NEV-801) is under development for the treatment of advanced malignancy and solid tumors. It is administered through intravenous route. Podophyllotoxin acts by targeting DNA topoisomerase II whereas camptothecin acts by targeting DNA topoisomerase I. It was also under development for the treatment of ovarian cancer, resistant colorectal cancer, non-small cell lung cancer and targeted-therapy resistant chronic myeloid leukemia.
For a complete picture of (Camptothecin + podofilox)’s drug-specific PTSR and LoA scores, buy the report here.